Kimberly Lynn Blackwell, MD

Adjunct Professor in the Department of Medicine
Member of the Duke Cancer Institute
Campus mail Duke Box 3893, Durham, NC 27710
Phone (919) 668-1748
Email address black034@mc.duke.edu

Breast cancer angiogenesis
Breast cancer in younger women
Hormonal therapy
Neoadjurant therapy for breast cancer

Current Clinical Investigations

Principal Investigator, A Phase I-II Study of Neoadjuvant Evacet/Paclitaxel/Hyperthermia in Locally Advanced Breast Cancer Patients.

Investigator, Development of Screening Markers for Breast Cancer using Circulating Immune Complexes: Collaborative Study with Diagen Medical Technologies.

Principal Investigator, Use of Plasma D-Dimer as a Predictive Marker in Colorectal Carcinoma: Correlative Science Study with Genentech, Inc.

Principal Investigator, A randomized, Phase II study of gabapentin or glutamine to prevent the peripheral neuropathy/myalgia associated with weekly taxol administration in metastatic breast and lung cancer.

Investigator, A Phase 2, Randomized, Double-Masked, Multicenter Study of Two Dose Levels of ERA-923 for the treatment of Metastatic Breast Cancer in Postmenopausal Women who have failed Tamoxifen therapy. Genetics Institute.

Investigator, A Phase I Study of Combined Doxil/Hyperthermia in Stage IV Breast Cancer.

Education and Training

  • Fellow in Hematology-Oncology, Medicine, Duke University, 1997 - 2000
  • Medical Resident, Medicine, Duke University, 1994 - 1997
  • M.D., Mayo School of Health Sciences, 1994

Publications

Hamilton, E, Blackwell, K, Hobeika, AC, Clay, TM, Broadwater, G, Ren, X-R, Chen, W, Castro, H, Lehmann, F, Spector, N, Wei, J, Osada, T, Lyerly, HK, and Morse, MA. "Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected]." Journal of Translational Medicine 10 (February 10, 2012): 28-null.

PMID
22325452
Full Text

Wu, Y, Amonkar, MM, Sherrill, BH, O'Shaughnessy, J, Ellis, C, Baselga, J, Blackwell, KL, and Burstein, HJ. "Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer." Annals of Oncology 22, no. 12 (December 2011): 2582-2590.

PMID
21406472
Full Text

Hamilton, E, Clay, TM, and Blackwell, KL. "New perspectives on zoledronic acid in breast cancer: potential augmentation of anticancer immune response." Cancer Investigation 29, no. 8 (October 2011): 533-541. (Review)

PMID
21843051
Full Text

Herold, CI, Chadaram, V, Peterson, BL, Marcom, PK, Hopkins, J, Kimmick, GG, Favaro, J, Hamilton, E, Welch, RA, Bacus, S, and Blackwell, KL. "Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosing." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 17, no. 18 (September 2011): 6061-6070.

PMID
21810917
Full Text

Xia, W, Liu, Z, Zong, R, Liu, L, Zhao, S, Bacus, SS, Mao, Y, He, J, Wulfkuhle, JD, Petricoin, EF, Osada, T, Yang, X-Y, Hartman, ZC, Clay, TM, Blackwell, KL, Lyerly, HK, and Spector, NL. "Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors." Molecular Cancer Therapeutics 10, no. 8 (August 2011): 1367-1374.

PMID
21673090
Full Text

Morse, MA, Chapman, R, Powderly, J, Blackwell, K, Keler, T, Green, J, Riggs, R, He, L-Z, Ramakrishna, V, Vitale, L, Zhao, B, Butler, SA, Hobeika, A, Osada, T, Davis, T, Clay, T, and Lyerly, HK. "Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 17, no. 14 (July 2011): 4844-4853.

PMID
21632857
Full Text

Gatza, ML, Kung, H-N, Blackwell, KL, Dewhirst, MW, Marks, JR, and Chi, J-T. "Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes." Breast Cancer Research : Bcr 13, no. 3 (June 7, 2011): R62-null.

PMID
21672245
Full Text

Morse, MA, Secord, AA, Blackwell, K, Hobeika, AC, Sinnathamby, G, Osada, T, Hafner, J, Philip, M, Clay, TM, Lyerly, HK, and Philip, R. "MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer." Clin Cancer Res 17, no. 10 (May 15, 2011): 3408-3419.

PMID
21300761
Full Text

Anders, CK, Fan, C, Parker, JS, Carey, LA, Blackwell, KL, Klauber-DeMore, N, and Perou, CM. "Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes?." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 29, no. 1 (January 2011): e18-e20. (Letter)

PMID
21115855
Full Text

Hamilton, EP, and Blackwell, KL. "Safety of bevacizumab in patients with metastatic breast cancer." Oncology 80, no. 5-6 (2011): 314-325. (Review)

PMID
21778772
Full Text

Pages